Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ DARZALEX — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

BioMarin Pharmaceuticals logo
BMRNProducts excluding ALDURAZYME — Total revenues
$723.34M+5.5%
Ionis Pharmaceuticals logo
IONSDAWNZERA Sales — Revenue
$15.86M—
BioMarin Pharmaceuticals logo
BMRNALDURAZYME — Total revenues
$36.74M-25.0%
UroGen Pharma logo
URGNZusduri — Revenue
$29.25M—
Eli Lilly logo
LLYVerzenio — Revenue
$1.3B+12.3%
Pfizer logo
PFEXeljanz — Revenues:
$180M+40.6%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's darzalex — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's DARZALEX — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported DARZALEX — sales to customers (note 9) of $3.96B in Q1 2026.
How has Johnson & Johnson's DARZALEX — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's DARZALEX — sales to customers (note 9) increased by 22.5% year-over-year, from $3.24B to $3.96B.
What is the long-term trend for Johnson & Johnson's DARZALEX — sales to customers (note 9)?
Over 4 years (2021 to 2025), Johnson & Johnson's DARZALEX — sales to customers (note 9) has grown at a 24.2% compound annual growth rate (CAGR), from $6.02B to $14.35B.
What does DARZALEX — sales to customers (note 9) mean?
This metric represents the total net revenue generated from the sale of a specific high-growth oncology therapeutic product to external customers. It serves as a key indicator of the product's market adoption, clinical demand, and contribution to the company's overall pharmaceutical segment performance. Tracking this revenue stream helps investors assess the commercial success and lifecycle stage of a flagship specialty drug.